undefined undefined undefined

Great Debate: TAVI should be the first procedure if a biological valve is chosen

Event: ESC Congress 2025

Topic: Valves

Session type: Great Debates

Access

Like

Great Debate: following an acute coronary syndrome, the default duration of dual antiplatelet therapy should be 12 months

Event: ESC Congress 2025

Topic: Antiplatelet Agents

Session type: Great Debates

Access

Like

Unravelling cardiovascular inflammation in atherosclerotic cardiovascular disease (ASCVD): from evidence to guidance

Event: ESC Congress 2025

Topic: Inflammation

Session type: Satellite Symposium

Access

Like

Digital applications to guide precision cardiovascular interventions

Event: ESC Congress 2025

Topic: Computer Modelling and Simulation

Session type: Practical Seminar

Access

Like

Adjunctive antiplatelet therapy for patients undergoing percutaneous coronary intervention

Event: ESC Congress 2025

Topic: Adjunctive Pharmacotherapy

Session type: Advances in Science

Access

Like

HOT LINE 8

Event: ESC Congress 2024

Topic: European Society of Cardiology

Session type: Hot Line

Access

Like

Great Debate: mechanical circulatory support in cardiogenic shock - 'the course of true love never did run smooth'

Event: ESC Congress 2024

Topic: Clinical

Session type: Great Debates

Access

Like

Transforming TAVI practice: evidence, equity, and durability

Event: ESC Congress 2024

Topic: Valvular Heart Disease

Session type: Satellite Symposium

Access

Like

Innovations in cardiovascular medicine that impact clinical practice

Event: ESC Congress 2023

Topic: Clinical Skills

Session type: Official Joint Session

Access

Like

ESC TV Perspectives - Cardiogenic shock & OHCA: the problems and the solutions

Event: ESC Congress 2023

Topic: Acute Heart Failure

Session type: Special Session

Access

Like

undefined undefined undefined

Contributor content

Great Debate: TAVI should be the first procedure if a biological valve is chosen

Great Debate: following an acute coronary syndrome, the default duration of dual antiplatelet therapy should be 12 months

Unravelling cardiovascular inflammation in atherosclerotic cardiovascular disease (ASCVD): from evidence to guidance

Digital applications to guide precision cardiovascular interventions

Adjunctive antiplatelet therapy for patients undergoing percutaneous coronary intervention

HOT LINE 8

Great Debate: mechanical circulatory support in cardiogenic shock - 'the course of true love never did run smooth'

Transforming TAVI practice: evidence, equity, and durability

Innovations in cardiovascular medicine that impact clinical practice

ESC TV Perspectives - Cardiogenic shock & OHCA: the problems and the solutions

ESC 365 is supported by